Literature DB >> 22365064

Benefits of ambulatory axillary intra-aortic balloon pump for circulatory support as bridge to heart transplant.

Ramanan Umakanthan1, Steven J Hoff, Natalia Solenkova, Mark A Wigger, Mary E Keebler, Andrew Lenneman, Marzia Leacche, Thomas G Disalvo, Henry Ooi, Allen J Naftilan, John G Byrne, Rashid M Ahmad.   

Abstract

OBJECTIVE: Axillary intra-aortic balloon pump therapy has been described as a bridge to transplant. Advantages over femoral intra-aortic balloon pump therapy include reduced incidence of infection and enhanced patient mobility. We identified the patients who would benefit most from this therapy while awaiting heart transplantation.
METHODS: We conducted a single-center, retrospective observational study to evaluate outcomes from axillary intra-aortic balloon pump therapy. These included hemodynamic parameters, duration of support, and success in bridging to transplant. We selected patients on the basis of history of sternotomy, elevated panel-reactive antibody, and small body habitus. Patients were made to ambulate aggressively beginning on postoperative day 1.
RESULTS: Between September 2007 and September 2010, 18 patients underwent axillary intra-aortic balloon pump therapy. All patients had the devices placed through the left axillary artery with a Hemashield side graft (Boston Scientific, Natick, Mass). Before axillary placement, patients underwent femoral placement to demonstrate hemodynamic benefit. Duration of support ranged from 5 to 63 days (median = 19 days). There was marked improvement in ambulatory potential and hemodynamic parameters, with minimal blood transfusion requirements. There were no device-related infections. Some 72% of the patients (13/18) were successfully bridged to transplantation.
CONCLUSIONS: Axillary intra-aortic balloon pump therapy provides excellent support for selected patients as a bridge to transplant. The majority of the patients were successfully bridged to transplant and discharged. Although this therapy has been described in previous studies, this is the largest series to incorporate a regimen of aggressive ambulation with daily measurements of distances walked.
Copyright © 2012. Published by Mosby, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22365064     DOI: 10.1016/j.jtcvs.2012.02.009

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

Review 1.  Frailty in the End-Stage Lung Disease or Heart Failure Patient: Implications for the Perioperative Transplant Clinician.

Authors:  Brandi A Bottiger; Alina Nicoara; Laurie D Snyder; Paul E Wischmeyer; Jacob N Schroder; Chetan B Patel; Mani A Daneshmand; Robert N Sladen; Kamrouz Ghadimi
Journal:  J Cardiothorac Vasc Anesth       Date:  2018-08-09       Impact factor: 2.628

Review 2.  Ambulatory Intra Aortic Balloon Pump in Advanced Heart Failure.

Authors:  Syed Yaseen Naqvi; Ibrahim G Salama; Ayhan Yoruk; Leway Chen
Journal:  Card Fail Rev       Date:  2018-05

3.  Five years' experience with a peripheral veno-arterial ECMO for mechanical bridge to heart transplantation.

Authors:  Vitaly Poptsov; Ekaterina Spirina; Anastasiya Dogonasheva; Elizaveta Zolotova
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

Review 4.  Evidence of clinical efficacy of counterpulsation therapy methods.

Authors:  M Capoccia; C T Bowles; J R Pepper; N R Banner; A R Simon
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

5.  Intra-Aortic Balloon Pump Bridging to Heart Transplantation: Impact of the 2018 Allocation Change.

Authors:  Lauren V Huckaby; Laura M Seese; Michael A Mathier; Gavin W Hickey; Arman Kilic
Journal:  Circ Heart Fail       Date:  2020-08-06       Impact factor: 8.790

Review 6.  Mechanical Support in Early Cardiogenic Shock: What Is the Role of Intra-aortic Balloon Counterpulsation?

Authors:  Jesse R Kimman; Nicolas M Van Mieghem; Henrik Endeman; Jasper J Brugts; Alina A Constantinescu; Olivier C Manintveld; Eric A Dubois; Corstiaan A den Uil
Journal:  Curr Heart Fail Rep       Date:  2020-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.